- Home
- IBOC vs HAE Comparison
IBOC vs HAE Comparison
Compare IBOC & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBOC
- HAE
- Stock Information
- Founded
- IBOC 1966
- HAE 1971
- Country
- IBOC United States
- HAE United States
- Employees
- IBOC N/A
- HAE N/A
- Industry
- IBOC Major Banks
- HAE Medical/Dental Instruments
- Sector
- IBOC Finance
- HAE Health Care
- Exchange
- IBOC Nasdaq
- HAE Nasdaq
- Market Cap
- IBOC 3.8B
- HAE 3.3B
- IPO Year
- IBOC N/A
- HAE 1991
- Fundamental
- Price
- IBOC $69.34
- HAE $49.94
- Analyst Decision
- IBOC
- HAE Buy
- Analyst Count
- IBOC 0
- HAE 10
- Target Price
- IBOC N/A
- HAE $84.20
- AVG Volume (30 Days)
- IBOC 194.1K
- HAE 949.0K
- Earning Date
- IBOC 11-06-2025
- HAE 11-06-2025
- Dividend Yield
- IBOC 2.03%
- HAE N/A
- EPS Growth
- IBOC 1.85
- HAE 46.89
- EPS
- IBOC 6.61
- HAE 3.28
- Revenue
- IBOC $808,643,000.00
- HAE $1,346,046,000.00
- Revenue This Year
- IBOC N/A
- HAE N/A
- Revenue Next Year
- IBOC N/A
- HAE $6.50
- P/E Ratio
- IBOC $10.42
- HAE $15.31
- Revenue Growth
- IBOC 1.28
- HAE 0.91
- 52 Week Low
- IBOC $54.11
- HAE $49.43
- 52 Week High
- IBOC $76.91
- HAE $94.99
- Technical
- Relative Strength Index (RSI)
- IBOC 44.64
- HAE 24.83
- Support Level
- IBOC $68.23
- HAE $53.10
- Resistance Level
- IBOC $71.36
- HAE $54.52
- Average True Range (ATR)
- IBOC 1.34
- HAE 1.28
- MACD
- IBOC -0.36
- HAE 0.21
- Stochastic Oscillator
- IBOC 20.75
- HAE 8.40
About IBOC International Bancshares Corporation
International Bancshares Corp is a multibank financial holding company. The company provides commercial and retail banking services in Texas and Oklahoma. The services provided by the bank include checking, savings, bank cards, lending, insurance, mortgage, investments, and other services.
About HAE Haemonetics Corporation
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.